J 2021

Cross-oncopanel study reveals high sensitivity and accuracy with overall analytical performance depending on genomic regions

GONG, B.S., D. LI, R. KUSKO, N. NOVORADOVSKAYA, Y.F. ZHANG et. al.

Basic information

Original name

Cross-oncopanel study reveals high sensitivity and accuracy with overall analytical performance depending on genomic regions

Authors

GONG, B.S., D. LI, R. KUSKO, N. NOVORADOVSKAYA, Y.F. ZHANG, S.Z. WANG, C. PABON-PENA, Z.H. ZHANG, K. LAI, W.S. CAI, J.S. LOCOCO, E. LADER, T.A. RICHMOND, V.K. MITTAL, L.C. LIU, D.J. JOHANN, J.C. WILLEY, P.R. BUSHEL, Y. YU, C. XU, G.C. CHEN, D. BURGESS, S. CAWLEY, K. GIORDA, N. HASELEY, F.J. QIU, K. WILKINS, H. ARIB, C. ATTWOOLL, K. BABSON, L.L. BAO, W.J. BAO, A.B. LUCAS, H. BEST, A. BHANDARI, H. BISGIN, J. BLACKBURN, T.M. BLOMQUIST, L. BOARDMAN, B. BURGHER, D.J. BUTLER, C.J. CHANG, A. CHAUBEY, T. CHEN, M. CHIERICI, C.R. CHIN, D. CLOSE, J. CONROY, J.C. COLEMAN, D.J. CRAIG, E. CRAWFORD, A. DEL POZO, I.W. DEVESON, D. DUNCAN, A.K. ETEROVIC, X.H. FAN, J. FOOX, C. FURLANELLO, A. GHOSAL, S. GLENN, M.J. GUAN, C. HAAG, X.Y. HANG, S. HAPPE, B. HENNIGAN, J. HIPP, H.X. HONG, K. HORVATH, J.H. HU, L.Y. HUNG, M. JAROSZ, J. KERKHOF, B. KIPP, D.P. KREIL, P. LAPUNZINA, P. LI, Q.Z. LI, W.H. LI, Z.G. LI, Y. LIANG, S.Q. LIU, Z.C. LIU, C. MA, N. MARELLA, R. MARTIN-ARENAS, D.B. MEGHERBI, Q.C. MENG, P.A. MIECZKOWSKI, T. MORRISON, D. MUZNY, B.T. NING, B.L. PARSONS, C.P. PAWELETZ, M. PIROOZNIA, W.B. QU, A. RAYMOND, P. RINDLER, R. RINGLER, B. SADIKOVIC, A. SCHERER, E. SCHULZE, R. SEBRA, R. SHAKNOVICH, Q. SHI, T.L. SHI, J.C. SILLA-CASTRO, M. SMITH, M.S. LOPEZ, P. SONG, D. STETSON, M. STRAHL, A. STUART, J. SUPPLEE, P. SZANKASI, H.W. TAN, L.Y. TANG, Y.H. TAO, S. THAKKAR, D. THIERRY-MIEG, J. THIERRY-MIEG, V.J. THODIMA, D. THOMAS, Boris TICHÝ (203 Czech Republic, belonging to the institution), Nikola TOM (203 Czech Republic, belonging to the institution), E.V. GARCIA, S. VERMA, K. WALKER, C. WANG, J.W. WANG, Y.X. WANG, Z.N. WEN, V. WIRTA, L.H. WU, C.L. XIAO, W.Z. XIAO, S.B. XU, M. YANG, J.M. YING, S.H. YIP, G.L. ZHANG, S. ZHANG, M.R. ZHAO, Y.T. ZHENG, X.Y. ZHOU, C.E. MASON, T. MERCER, W.D. TONG, L.M. SHI, W. JONES and J.S. XU

Edition

GENOME BIOLOGY, LONDON, BIOMED CENTRAL LTD, 2021, 1474-760X

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 17.906

RIV identification code

RIV/00216224:14740/21:00120110

Organization unit

Central European Institute of Technology

UT WoS

000641654300001

Keywords in English

Oncopanel sequencing; Target enrichment; Molecular diagnostics; Reproducibility; Analytical performance; Precision medicine

Tags

Tags

International impact, Reviewed
Změněno: 15/10/2024 14:26, Ing. Martina Blahová

Abstract

V originále

BackgroundTargeted sequencing using oncopanels requires comprehensive assessments of accuracy and detection sensitivity to ensure analytical validity. By employing reference materials characterized by the U.S. Food and Drug Administration-led SEquence Quality Control project phase2 (SEQC2) effort, we perform a cross-platform multi-lab evaluation of eight Pan-Cancer panels to assess best practices for oncopanel sequencing.ResultsAll panels demonstrate high sensitivity across targeted high-confidence coding regions and variant types for the variants previously verified to have variant allele frequency (VAF) in the 5-20% range. Sensitivity is reduced by utilizing VAF thresholds due to inherent variability in VAF measurements. Enforcing a VAF threshold for reporting has a positive impact on reducing false positive calls. Importantly, the false positive rate is found to be significantly higher outside the high-confidence coding regions, resulting in lower reproducibility. Thus, region restriction and VAF thresholds lead to low relative technical variability in estimating promising biomarkers and tumor mutational burden.ConclusionThis comprehensive study provides actionable guidelines for oncopanel sequencing and clear evidence that supports a simplified approach to assess the analytical performance of oncopanels. It will facilitate the rapid implementation, validation, and quality control of oncopanels in clinical use.

Links

LM2015064, research and development project
Name: Český národní uzel Evropské infrastruktury pro translační medicínu (Acronym: EATRIS-ERIC-CZ)
Investor: Ministry of Education, Youth and Sports of the CR
LM2018133, research and development project
Name: Český národní uzel Evropské infrastruktury pro translační medicínu (Acronym: EATRIS-ERIC-CZ)
Investor: Ministry of Education, Youth and Sports of the CR
LQ1601, research and development project
Name: CEITEC 2020 (Acronym: CEITEC2020)
Investor: Ministry of Education, Youth and Sports of the CR
NV19-03-00091, research and development project
Name: Komplexní prognostický a prediktivní panel pro pacienty s chronickou lymfocytární leukémií: nástroj sekvenování nové generace vhodný pro klinickou praxi i studium genetického pozadí průběhu choroby
Investor: Ministry of Health of the CR
90132, large research infrastructures
Name: NCMG II